Connor, Clark & Lunn Investment Management (CC&L)’s Tvardi Therapeutics TVRD Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,215	Closed	-$1.41M	–	1226
2022 Q1	$1.41M	Sell	3,215 -615	-16%	-$252K	0.01%	592
2021 Q4	$1.68M	Sell	3,830 -271	-7%	-$136K	0.01%	573
2021 Q3	$2.28M	Buy	+4,101	New	+$2.06M	0.01%	501
2015 Q2	–	Sell	-306	Closed	-$111K	–	671
2015 Q1	$111K	Buy	+306	New	+$116K	﹤0.01%	531

Other funds holding TVRD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TVRD Position: Q2 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Tvardi Therapeutics (TVRD) in Q2 2022, closing a stake of 3,215 shares — an estimated $1.41M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TVRD in Q1 2015 and held it in 4 quarters. The position peaked at $2.28M in Q3 2021. 179 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Tvardi Therapeutics position as of Q2 2022 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 3,215 Tvardi Therapeutics shares in Q2 2022, an estimated $1.41M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Tvardi Therapeutics in Q1 2015 and held it in 4 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Tvardi Therapeutics position peaked at $2.28M in Q3 2021.
179 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2022, filed 5 Aug 2022.